查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1931288

2026-2032年全球肺炎链球菌13价结合疫苗市场（依最终用户、适应症及剂型划分）预测

Pneumococcal 13-valent Conjugate Vaccine Market by End User, Indication, Formulation - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年肺炎链球菌13价结合疫苗市场规模为39.8亿美元，预计2026年将达42亿美元，到2032年将达到62.3亿美元，复合年增长率为6.59%。

主要市场统计数据
基准年 2025 39.8亿美元
预计年份：2026年 42亿美元
预测年份：2032年 62.3亿美元
复合年增长率 (%) 6.59%

目前13价肺炎链球菌疫苗环境的重点方向：明确临床价值、营运重点与策略决策点

肺炎链球菌感染仍然是所有年龄层中疫苗可预防疾病和死亡的主要原因，13价结合疫苗仍然是许多免疫接种计划中预防策略的基石。本文将PCV13置于更广泛的免疫生态系统中，重点阐述了该疫苗在常规儿童免疫接种计划、成人加强免疫策略以及针对高危险群的公共卫生宣传活动中的作用。监管核准情况的变化、高剂量疫苗的出现以及采购政策的转变，都导致了竞争格局和项目选择的变化。

技术创新、包装差异化和采购重点的转变如何重塑PCV13疫苗的竞争策略和专案选择

肺炎链球菌疫苗市场正经历着变革性的转变，其驱动因素包括结合疫苗设计的技术进步、监管预期的变化以及公共和私人支付方采购方式的改变。新型高剂量疫苗的出现促使人们重新评估现有的免疫接种方案，进而影响了对传统13价疫苗的需求。同时，生产商正透过包装创新实现差异化，例如预填充式注射器以方便即时接种，以及推出多剂量管瓶以支持资源匮乏环境下的大规模宣传活动。这些包装选择影响低温运输物流和接种效率，进而影响整个医疗保健系统的采购重点。

评估截至2025年的累积关税如何加速疫苗供应链的来源多元化、采购流程重组和包装权衡。

美国在2025年前实施的累积关税及相关贸易应对措施，促使疫苗供应链各环节重新评估筹资策略、製造地及采购时间表。製造商和经销商正透过供应商多元化、将部分生产流程转移到更靠近终端市场的地方以及重新谈判合约条款来应对，以减轻额外进口成本对下游采购商的影响。这些供应面的调整对库存管理政策和竞标计划週期产生了连锁反应，促使公共和私人采购商寻求透过长期合约和本地生产伙伴关係来获得更可靠的供应保障。

详细的細項分析揭示了不同年龄层、最终用户、分销管道、适应症和製剂形式之间存在的明显临床优先事项、采购行为和分销要求。

细分市场分析表明，不同年龄层、最终用户、分销管道、适应症和剂型的需求驱动因素和营运重点各不相同，凸显了製定客製化商业策略的必要性。依年龄组别划分，13-17岁青少年、18-49岁成年人、2-12岁儿童、0-2岁婴儿和50岁以上老年人的临床需求和疫苗接种接触点各不相同。这意味着临床讯息、接种方案和推广策略必须根据各年龄层的医疗环境和支付方的期望进行调整。最终用户的细分导致了采购週期和合约要求的差异，这主要是由于私营和公共部门采购者的差异造成的。民营市场优先考虑便利性和分销管道的激活，而公共项目则优先考虑成本效益、低温运输效率和公平覆盖。

区域监管差异、采购机制和卫生系统能力如何推动重点区域采用不同的管道和项目优先事项？

区域动态影响筹资策略、监管参与以及专案交付管道的优先排序，每个区域都有其独特的营运实际情况和相关人员的期望。在美洲，免疫规划力求在集中采购与不断扩大的私部门活动和药房供应之间取得平衡，从而支持成人疫苗接种工作，并确保都市区儿童疫苗的广泛普及。在许多市场，过渡性法规结构和已建立的低温运输基础设施使得包装创新得以快速应用，但农村地区的疫苗可及性和健康公平性仍然是计画面临的关键挑战。

竞争优势需要结合传统临床信誉、策略製造伙伴关係和通路特定商业化，以实现竞争定位。

PCV13疫苗市场的竞争格局融合了传统的产品管理、策略性的生命週期管理以及生产合作伙伴和经销商之间的协作。现有生产者不断累积临床数据和真实世界证据，以支持各年龄层的常规免疫接种，但新参与企业和高滴度疫苗的出现迫使现有生产商重新定义其差异化提案，而这些优势的核心在于疫苗的适用性、接种成本和供应安全。随着企业寻求应对产能限制并降低贸易中断风险，包括契约製造和区域灌装包装伙伴关係在内的协作安排正变得越来越普遍。

采取切实可行的策略行动，增强供应链韧性，收集证据，并针对特定管道实现商业化，同时与公共卫生优先事项保持一致。

产业领导者应优先考虑供应链韧性、合规性和差异化价值提案，以避免市场萎缩风险并抓住策略机会。透过购买多元化和区域性填充包装合约提高生产柔软性，可以降低关税相关成本并缩短前置作业时间。同时，使监管申报和上市后证据的生成与区域监管预期保持一致，可以加快专案实施并增强竞争性竞标。在商业方面，企业应根据特定终端使用者和分销管道客製化产品和服务，确保包装和培训材料能够满足各个场所（例如政府诊所、医院药房、零售药房和电商履约网络）的实际情况。

采用严谨的混合方法调查方法，整合相关人员访谈、监管审查和证据三角验证，以得出可操作的专案见解。

本执行摘要摘要的研究整合了一级资讯来源和二级资讯来源，透过对监管文件、同行评审的临床文献、采购文件和相关人员访谈进行三角验证，从而对PCV13市场趋势检验全面的了解。一级资讯来源包括对免疫专案经理、医院药房主任、商业负责人和分销专家的结构化访谈，以了解决策驱动因素、物流限制和采购标准。第二手资料涵盖了监管指南、已发表的疫苗效力研究以及对不同医疗机构低温运输和给药实践的营运分析。研究人员还审查了来自监测网络和公共卫生报告的数据，以了解流行病学趋势的背景，从而为队列优先排序和计画实施时间决策提供基础。

综合考虑临床意义、营运权衡和策略重点，我们重点阐述了相关人员如何协调一致以维持有效的肺炎球菌疫苗接种计划。

本执行摘要指出，儘管PCV13疫苗在多个年龄层中仍是重要的临床工具，但其未来的部署正受到包装选择、供应链趋势和采购行为的影响。相关人员必须权衡多剂量管瓶和预填充式注射器之间的利弊，平衡近期宣传活动的需求与可靠的供应，并调整商业策略以满足公共和私营部门的不同期望。贸易政策变化带来的累积效应进一步凸显了在地化生产和多元化供应管道的必要性，以确保疫苗供应的连续性，并保护免疫接种计划免受干扰。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依最终用户分類的13价肺炎链球菌结合疫苗市场

  • 私部门
  • 公共部门

9. 依适应症分類的13价肺炎链球菌结合疫苗市场

  • 加强疫苗接种
  • 补种疫苗
  • 首次接种疫苗

10. 肺炎链球菌13价结合疫苗市场（以剂型划分）

  • 多剂量管瓶
  • 预填充式注射器

11. 各地区13价肺炎链球菌结合疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 肺炎链球菌13价结合疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各国13价肺炎链球菌结合疫苗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国13价肺炎链球菌结合疫苗市场

17. 中国13价肺炎链球菌结合疫苗市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Biological E. Limited
  • Chongqing Taibang Biological Products Co., Ltd.
  • GlaxoSmithKline plc
  • Inventprise
  • Merck & Co., Inc.
  • Panacea BIoTec Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • SK bioscience Co., Ltd.
  • Vaxcyte
  • Walvax BIoTechnology Co., Ltd.
Product Code: MRR-7B550E008E0C

The Pneumococcal 13-valent Conjugate Vaccine Market was valued at USD 3.98 billion in 2025 and is projected to grow to USD 4.20 billion in 2026, with a CAGR of 6.59%, reaching USD 6.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.98 billion
Estimated Year [2026] USD 4.20 billion
Forecast Year [2032] USD 6.23 billion
CAGR (%) 6.59%

A focused orientation to the current pneumococcal 13-valent vaccine environment clarifying clinical value, operational priorities, and strategic decision points

Pneumococcal disease remains a leading cause of vaccine-preventable morbidity and mortality across age cohorts, and the 13-valent conjugate vaccine continues to be a cornerstone of prevention strategies in many immunization schedules. This introduction situates the PCV13 landscape within a broader immunization ecosystem, highlighting the vaccine's role in routine pediatric schedules, adult revaccination strategies, and targeted public health campaigns aimed at at-risk populations. Recent shifts in regulatory approvals, the emergence of higher-valent alternatives, and evolving procurement preferences have collectively altered competitive dynamics and programmatic choices.

Understanding the current environment requires attention to supply chain resilience, packaging preferences such as multi-dose vials versus pre-filled syringes, and the complex interplay between public sector tenders and private market demand. Moreover, demographic transitions and changing disease epidemiology influence priority populations, with older adults and infants continuing to be focal points for immunization efforts. This section frames the subsequent analysis by clarifying the vaccine's clinical rationale, operational considerations in administration and storage, and the strategic questions that stakeholders must address to optimize uptake and program impact. Transitional discussion will connect these foundational considerations to segmentation, regional nuances, and competitive behavior addressed later in the executive summary.

How technological innovation, packaging differentiation, and shifting procurement priorities are reshaping competitive strategies and programmatic choices in the PCV13 landscape

The pneumococcal vaccine landscape is experiencing transformative shifts driven by technological advances in conjugate design, evolving regulatory expectations, and changing procurement practices among public and private payers. Newer higher-valent vaccines have prompted reassessments of existing immunization schedules, which in turn influences demand for legacy 13-valent products. At the same time, manufacturers are differentiating through packaging innovations, such as pre-filled syringes for point-of-care convenience and multi-dose vials to support mass campaigns in resource-constrained settings. These packaging choices affect cold-chain logistics and administration efficiency, thereby shaping procurement preferences across health systems.

Concurrently, policy and payer trends are encouraging value-based evaluation of vaccines, emphasizing real-world effectiveness, herd protection, and reduced healthcare utilization. Public sector procurers are increasingly focused on tender structures that reward supply reliability and total cost of administration rather than unit price alone. Private sector channels are adapting through digital engagement and pharmacy-based immunization programs that improve access but require consistent supply and physician education. As a result, competitive strategies are shifting from purely clinical messaging to integrated offerings that combine product, packaging, and service elements to meet diverse stakeholder needs. The next sections explore how these shifts interact with regional dynamics and segmentation nuances to define future opportunities and risks.

Assessing how cumulative tariff measures through 2025 have accelerated supply diversification, procurement reengineering, and packaging trade-offs across vaccine supply chains

Cumulative tariff measures implemented in the United States and related trade responses through 2025 have driven a reassessment of sourcing strategies, manufacturing footprints, and procurement timelines across the vaccine supply chain. Manufacturers and distributors have responded by diversifying suppliers, relocating certain production steps closer to end markets, and renegotiating contractual terms to mitigate the impact of added import costs on downstream purchasers. These supply-side adjustments have had ripple effects on inventory management policies and tender planning horizons, prompting both public and private buyers to seek greater supply assurance through longer-term agreements or local manufacturing partnerships.

For immunization programs, the tariff environment has amplified the importance of packaging format decisions; multi-dose vials, which lower per-dose handling costs and cold-chain footprint, are juxtaposed against pre-filled syringes that offer ease of use but higher unit logistics costs. Procurement bodies are increasingly incorporating total administration cost assessments into purchasing criteria to balance these trade-offs. Moreover, transitional contingency planning has become central to procurement governance, encouraging stakeholders to build flexibility into ordering cycles and to prioritize transparency in supplier reporting. Ultimately, the cumulative tariff environment has accelerated structural changes in supply chain resilience and procurement behavior that will influence how PCV13 is sourced, distributed, and administered through the near term.

Granular segmentation reveals distinct clinical priorities, procurement behaviors, and distribution requirements across age cohorts, end users, channels, indications, and formulations

Segmentation insights reveal how demand drivers and operational priorities vary by age, end user, distribution channel, indication, and formulation, underscoring the need for tailored commercial approaches. Based on age group, populations of Adolescents 13-17 Years, Adults 18-49 Years, Children 2-12 Years, Infants 0-2 Years, and Older Adults 50+ Years each exhibit distinct clinical priorities and immunization touchpoints, meaning that clinical messaging, dosing schedules, and outreach tactics must be calibrated to age-specific care settings and payer expectations. Based on end user, the dichotomy between Private Sector and Public Sector purchasers produces divergent procurement cycles and contractual requirements; private markets often emphasize convenience and channel activation, whereas public programs prioritize cost-effectiveness, cold-chain efficiency, and equitable coverage.

Based on distribution channel, platforms such as E-Commerce Platforms, Government Clinics, Hospital Pharmacies, and Retail Pharmacies require differentiated availability strategies, temperature-controlled logistics, and educational materials tailored to point-of-care staff. Based on indication, whether the focus is Booster Immunization, Catch-Up Immunization, or Primary Immunization determines dosing schedules, target cohorts, and monitoring needs, with catch-up campaigns demanding higher short-term volume and booster strategies relying on robust adult uptake channels. Based on formulation, the choice between Multi-Dose Vial and Pre-Filled Syringe influences procurement preferences, waste management practices, and on-site handling capabilities. Integrating these segmentation dimensions enables more precise targeting of evidence generation, commercial incentives, and operational investments across stakeholders.

How regional regulatory diversity, procurement mechanisms, and health system capabilities are driving differentiated adoption paths and program priorities across major geographies

Regional dynamics shape prioritization of procurement strategies, regulatory engagement, and program implementation pathways, with each geography presenting unique operational realities and stakeholder expectations. In the Americas, immunization programs balance centralized procurement with growing private sector activity and pharmacy-based delivery, which supports adult revaccination efforts and broad access to pediatric immunizations in urban centers. Transitional regulatory frameworks and established cold-chain infrastructure in many markets enable rapid adoption of packaging innovations, although rural access and health equity remain central programmatic concerns.

In Europe, Middle East & Africa, regulatory heterogeneity and divergent purchasing mechanisms create a patchwork of adoption timelines; some countries employ joint procurement frameworks and sophisticated surveillance systems while others face logistical constraints that influence the preference for multi-dose vials to maximize coverage. Policy makers in these regions emphasize cost-effectiveness and supply security alongside efforts to strengthen immunization registries. Meanwhile, in Asia-Pacific, rapid urbanization, expanding private healthcare spending, and concentrated manufacturing capacity have fostered both competitive manufacturing investments and demand segmentation between public tenders and private clinic channels. Cross-cutting themes across all regions include the need for stronger surveillance data to guide program adjustments and the importance of supply chain resilience to sustain immunization continuity.

Competitive positioning blends legacy clinical credibility, strategic manufacturing partnerships, and channel-specific commercialization to secure programmatic advantage

Competitive dynamics within the PCV13 landscape reflect a blend of legacy product stewardship, strategic lifecycle management, and collaboration across manufacturing partners and distributors. Established manufacturers continue to maintain clinical and real-world evidence dossiers that support routine use across age cohorts, while new entrants and higher-valent alternatives are prompting incumbent players to articulate differentiating propositions focused on programmatic fit, cost of administration, and supply reliability. Collaborative arrangements, including toll-manufacturing and regional fill-finish partnerships, have become more prevalent as companies seek to manage capacity constraints and reduce exposure to trade disruptions.

Manufacturers are also investing in post-marketing surveillance and health economics studies to demonstrate broader public health value, including indirect protection and reductions in healthcare utilization. On the commercial side, firms are exploring channel-specific strategies that engage hospital systems, retail pharmacies, and digital platforms to enhance access and adherence, particularly for adult booster programs. Strategic alliances with local distributors and targeted education campaigns for immunizers support market penetration in heterogeneous regulatory environments. As a result, competitive advantage increasingly derives from a combination of clinical credibility, operational agility, and the ability to offer integrated solutions that align with purchaser priorities rather than from product attributes alone.

Practical strategic actions to fortify supply resilience, evidence generation, and channel-specific commercialization while aligning with public health priorities

Industry leaders should prioritize supply resilience, regulatory alignment, and differentiated value propositions to navigate displacement risk and capture strategic opportunities. Strengthening manufacturing flexibility through diversified sourcing and regional fill-finish agreements will reduce exposure to tariff-related costs and shorten lead times. At the same time, aligning regulatory submissions and post-marketing evidence generation with regional authority expectations accelerates program inclusion and supports tender competitiveness. Commercially, firms should tailor offerings to distinct end users and distribution channels, ensuring that packaging and training materials address the operational realities of government clinics, hospital pharmacies, retail pharmacies, and e-commerce fulfillment networks.

Additionally, companies should expand collaborations with public health agencies to co-design catch-up campaigns and adult booster strategies that leverage existing immunization platforms. Investing in real-world effectiveness studies and health economic modeling will strengthen value narratives for payers and procurement bodies while enabling outcome-based contracting conversations. Finally, improving digital engagement for both clinicians and patients will support adherence to multi-dose schedules and booster uptake. By integrating these priorities into a cohesive strategic plan, leaders can protect existing franchises, facilitate responsible lifecycle management, and unlock new channels for sustainable uptake.

A rigorous mixed-methods research approach integrating stakeholder interviews, regulatory review, and evidence triangulation to produce actionable programmatic insights

The research underpinning this executive summary synthesizes primary and secondary sources, triangulating regulatory filings, peer-reviewed clinical literature, procurement documentation, and stakeholder interviews to build a robust view of the PCV13 landscape. Primary inputs included structured interviews with immunization program managers, hospital pharmacy directors, commercial leaders, and distribution specialists to capture decision drivers, logistical constraints, and procurement criteria. Secondary research encompassed regulatory guidance, published vaccine effectiveness studies, and operational analyses of cold-chain and administration practices in diverse healthcare settings. Data from surveillance networks and public health reports were reviewed to contextualize epidemiologic trends that inform cohort prioritization and program timing.

Analytical methods combined qualitative thematic analysis with scenario-based assessments to evaluate the implications of tariffs, packaging preferences, and distribution channel shifts. Cross-validation procedures were applied to ensure consistency across stakeholder perspectives and documentary evidence, and limitations were transparently acknowledged where data granularity or recent policy changes constrained inference. The research approach emphasized practical relevance for commercial and public health decision makers, focusing on actionable insights rather than predictive metrics, and prioritized evidence that directly informs procurement, supply chain, and implementation strategies.

Synthesis of clinical relevance, operational trade-offs, and strategic priorities that stakeholders must align to sustain effective pneumococcal immunization programs

This executive synthesis underscores that the PCV13 vaccine remains a clinically important tool across multiple age cohorts, but its future trajectory is being reshaped by packaging choices, supply chain dynamics, and procurement behavior. Stakeholders must reconcile the trade-offs between multi-dose vials and pre-filled syringes, balance short-term campaign needs against steady-state supply reliability, and adapt commercial strategies to meet distinct public and private sector expectations. The cumulative effect of trade policy changes has reinforced the need for regional manufacturing and diversified supply channels to maintain continuity of access and protect immunization programs from disruption.

Looking ahead, successful programs will be those that combine sound clinical evidence with pragmatic operational planning and collaborative procurement frameworks. Decision makers should continue to invest in surveillance and health economic evidence to guide cohort prioritization while ensuring that logistical choices support equitable access. By aligning manufacturing, regulatory, and commercial approaches, stakeholders can uphold the public health benefits of pneumococcal immunization and respond nimbly to a changing competitive and policy landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumococcal 13-valent Conjugate Vaccine Market, by End User

  • 8.1. Private Sector
  • 8.2. Public Sector

9. Pneumococcal 13-valent Conjugate Vaccine Market, by Indication

  • 9.1. Booster Immunization
  • 9.2. Catch-Up Immunization
  • 9.3. Primary Immunization

10. Pneumococcal 13-valent Conjugate Vaccine Market, by Formulation

  • 10.1. Multi-Dose Vial
  • 10.2. Pre-Filled Syringe

11. Pneumococcal 13-valent Conjugate Vaccine Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Pneumococcal 13-valent Conjugate Vaccine Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Pneumococcal 13-valent Conjugate Vaccine Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Pneumococcal 13-valent Conjugate Vaccine Market

15. China Pneumococcal 13-valent Conjugate Vaccine Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Biological E. Limited
  • 16.6. Chongqing Taibang Biological Products Co., Ltd.
  • 16.7. GlaxoSmithKline plc
  • 16.8. Inventprise
  • 16.9. Merck & Co., Inc.
  • 16.10. Panacea Biotec Ltd.
  • 16.11. Pfizer Inc.
  • 16.12. Sanofi S.A.
  • 16.13. Serum Institute of India Pvt. Ltd.
  • 16.14. Shenzhen Kangtai Biological Products Co., Ltd.
  • 16.15. SK bioscience Co., Ltd.
  • 16.16. Vaxcyte
  • 16.17. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIVATE SECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIVATE SECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIVATE SECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PUBLIC SECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PUBLIC SECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PUBLIC SECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY BOOSTER IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY BOOSTER IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY BOOSTER IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY CATCH-UP IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY CATCH-UP IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY CATCH-UP IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIMARY IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIMARY IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIMARY IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. AMERICAS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 28. AMERICAS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 29. AMERICAS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 30. AMERICAS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 31. NORTH AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. NORTH AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. NORTH AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 34. NORTH AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 35. LATIN AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. LATIN AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. LATIN AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 38. LATIN AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 39. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 40. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 42. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 43. EUROPE PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. EUROPE PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. EUROPE PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 46. EUROPE PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 47. MIDDLE EAST PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. MIDDLE EAST PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. MIDDLE EAST PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. MIDDLE EAST PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 51. AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 54. AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. ASEAN PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. ASEAN PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. ASEAN PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 63. ASEAN PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 64. GCC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GCC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GCC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 67. GCC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPEAN UNION PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPEAN UNION PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPEAN UNION PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPEAN UNION PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 72. BRICS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. BRICS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. BRICS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. BRICS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 76. G7 PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. G7 PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. G7 PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. G7 PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 80. NATO PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NATO PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NATO PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NATO PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. UNITED STATES PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. UNITED STATES PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. UNITED STATES PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. UNITED STATES PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. CHINA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. CHINA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. CHINA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. CHINA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)